The treatment gap after major osteoporotic fractures in Denm
This study demonstrates a substantial and persistent anti-osteoporosis treatment gap in men and women more than 50 years old who sustained major osteoporotic fracture(s) between 2005 and 2014 in Denmark. This was not substantially reduced by including hospital-administered anti-osteoporosis treatments.

The purpose of this study was to evaluate the Danish anti-osteoporosis treatment gap from in patients sustaining a major osteoporotic fracture (MOF), and to assess the impact of including hospital-administered anti-osteoporosis medications (AOM) on the treatment gap among these patients.

A repeated cross-sectional design was applied to generate cohorts of patients sustaining a first MOF, hip, vertebral, humerus, or forearm fracture, respectively, within each calendar year. The treatment gap was evaluated as the proportion of patients within each cohort not receiving treatment with AOM within 1 year of the fracture. Hospital-administered AOM was identified by SKS code.

--The treatment gap among MOF patients decreased from 85% to 79%.
--The gap was smaller among hip and vertebral fracture patients as compared to humerus and forearm fracture patients, and it was smaller in women than in men.
--The use of hospital-administered AOM was relatively uncommon, with a maximum of 0.9% of MOF patients initiating hospital-administered AOM.
--Researchers observed substantial variations in this proportion between fracture types and gender.
--Hospital-administered AOM was most commonly used among vertebral fracture patients.

In conclusion, there was a substantial treatment gap among patients who sustained a major osteoporotic fracture during the study, and including hospital-administered AOM did not increase the treatment gap evaluation significantly. Improving secondary fracture prevention is important.